AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

The Phase III trials for AmyloSENS rejuvenation biotechnologies lecanemab/Leqembi® and donanemab showed that they are most effective when given to people with less of other kinds of cellular and molecular aging damage in their brains. New data illustrates that fact even more powerfully and gives us a foreshadowing of what’s possible if we make best use of these and forthcoming damage-repair longevity therapeutics.

Read more...

More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read more...

Sponsor a Student

SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.

Read more...

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

Read more...

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

Read more...

Announcing the Biomarkers of Aging Consortium

A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…

Read more...

Scenes from the Lab

Much of SRF’s research would not be possible without complex scientific equipment. SRF would like to thank its donors for their generous contributions which allow for the purchasing of this equipment, directly enabling research in ending age-related diseases.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: